 John Rice
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 5 | 2024 | 667 | 1.700 |
Why?
| | Papillomavirus Vaccines | 4 | 2025 | 243 | 1.170 |
Why?
| | Papillomavirus Infections | 4 | 2025 | 331 | 1.110 |
Why?
| | Likelihood Functions | 3 | 2024 | 143 | 0.880 |
Why?
| | Computer Simulation | 3 | 2024 | 986 | 0.780 |
Why?
| | Biometry | 2 | 2017 | 70 | 0.680 |
Why?
| | Critical Illness | 6 | 2025 | 809 | 0.670 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 224 | 0.650 |
Why?
| | Patient Acceptance of Health Care | 7 | 2025 | 809 | 0.650 |
Why?
| | Biostatistics | 1 | 2019 | 17 | 0.620 |
Why?
| | Statistical Distributions | 1 | 2017 | 8 | 0.570 |
Why?
| | Oxygen | 5 | 2025 | 943 | 0.530 |
Why?
| | Vaccination | 8 | 2025 | 1398 | 0.470 |
Why?
| | Mass Screening | 2 | 2022 | 1264 | 0.450 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2025 | 160 | 0.420 |
Why?
| | Hyperoxia | 3 | 2023 | 90 | 0.400 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1105 | 0.380 |
Why?
| | Sarcoma | 2 | 2025 | 192 | 0.370 |
Why?
| | Rhinitis | 2 | 2023 | 158 | 0.340 |
Why?
| | Sinusitis | 2 | 2023 | 221 | 0.320 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2249 | 0.320 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 358 | 0.290 |
Why?
| | Humans | 41 | 2025 | 137514 | 0.270 |
Why?
| | HIV Infections | 2 | 2019 | 2830 | 0.270 |
Why?
| | Lung Neoplasms | 3 | 2024 | 2494 | 0.260 |
Why?
| | Vaccines | 2 | 2022 | 411 | 0.250 |
Why?
| | Wounds and Injuries | 2 | 2025 | 752 | 0.250 |
Why?
| | Parents | 7 | 2025 | 1363 | 0.250 |
Why?
| | Vaccination Refusal | 3 | 2021 | 70 | 0.250 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 1079 | 0.240 |
Why?
| | Meta-Analysis as Topic | 2 | 2017 | 179 | 0.230 |
Why?
| | Vaccination Coverage | 1 | 2025 | 84 | 0.220 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 194 | 0.220 |
Why?
| | Touch Perception | 1 | 2024 | 19 | 0.220 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 81 | 0.220 |
Why?
| | Chronic Disease | 4 | 2023 | 1790 | 0.220 |
Why?
| | Cyclopentanes | 1 | 2023 | 20 | 0.210 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 135 | 0.210 |
Why?
| | Female | 20 | 2025 | 73162 | 0.210 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2024 | 72 | 0.200 |
Why?
| | Workload | 1 | 2024 | 163 | 0.200 |
Why?
| | Chemoradiotherapy | 1 | 2024 | 226 | 0.200 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 299 | 0.200 |
Why?
| | Stroke | 2 | 2022 | 1129 | 0.200 |
Why?
| | Pseudomonas | 1 | 2022 | 31 | 0.190 |
Why?
| | Sarcoma, Ewing | 1 | 2023 | 95 | 0.190 |
Why?
| | Length of Stay | 2 | 2024 | 1210 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1695 | 0.180 |
Why?
| | Endothelin-2 | 1 | 2021 | 2 | 0.180 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 250 | 0.180 |
Why?
| | Bone Remodeling | 1 | 2021 | 74 | 0.170 |
Why?
| | Private Practice | 1 | 2020 | 24 | 0.170 |
Why?
| | Bone Neoplasms | 1 | 2023 | 250 | 0.170 |
Why?
| | Burns | 1 | 2025 | 323 | 0.170 |
Why?
| | Prescription Drugs | 1 | 2022 | 110 | 0.170 |
Why?
| | Guideline Adherence | 2 | 2022 | 549 | 0.170 |
Why?
| | Pyrimidines | 1 | 2023 | 472 | 0.160 |
Why?
| | Biological Products | 1 | 2023 | 219 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2020 | 77 | 0.160 |
Why?
| | Intensive Care Units | 2 | 2025 | 803 | 0.160 |
Why?
| | Community Participation | 1 | 2020 | 131 | 0.160 |
Why?
| | Diet, High-Fat | 1 | 2021 | 248 | 0.160 |
Why?
| | Safety-net Providers | 1 | 2021 | 117 | 0.160 |
Why?
| | Mentoring | 1 | 2022 | 144 | 0.160 |
Why?
| | Prospective Studies | 8 | 2024 | 7598 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2024 | 1332 | 0.150 |
Why?
| | Child | 9 | 2025 | 22037 | 0.150 |
Why?
| | Hospitalists | 1 | 2023 | 245 | 0.150 |
Why?
| | Male | 17 | 2025 | 67718 | 0.140 |
Why?
| | Drug Resistant Epilepsy | 1 | 2019 | 102 | 0.140 |
Why?
| | Adult | 12 | 2025 | 37821 | 0.140 |
Why?
| | Homosexuality, Male | 1 | 2019 | 182 | 0.140 |
Why?
| | Health Risk Behaviors | 1 | 2017 | 16 | 0.140 |
Why?
| | Diagnostic Self Evaluation | 1 | 2017 | 23 | 0.140 |
Why?
| | Brain Injuries | 1 | 2023 | 493 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2019 | 117 | 0.140 |
Why?
| | Plant Extracts | 1 | 2019 | 203 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2019 | 218 | 0.140 |
Why?
| | Adolescent | 8 | 2025 | 21555 | 0.140 |
Why?
| | Ultrasonic Waves | 1 | 2017 | 6 | 0.140 |
Why?
| | Reminder Systems | 1 | 2019 | 176 | 0.130 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 395 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 607 | 0.130 |
Why?
| | Clinical Competence | 1 | 2024 | 1093 | 0.130 |
Why?
| | Paenibacillus | 1 | 2016 | 1 | 0.130 |
Why?
| | Endo-1,4-beta Xylanases | 1 | 2016 | 3 | 0.130 |
Why?
| | Xylans | 1 | 2016 | 4 | 0.130 |
Why?
| | Text Messaging | 1 | 2019 | 157 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2022 | 780 | 0.130 |
Why?
| | Glycoside Hydrolases | 1 | 2016 | 39 | 0.130 |
Why?
| | Capillaries | 1 | 2017 | 108 | 0.130 |
Why?
| | Patient Discharge | 1 | 2023 | 895 | 0.130 |
Why?
| | Probability | 1 | 2017 | 311 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2021 | 551 | 0.120 |
Why?
| | Physicians | 1 | 2024 | 904 | 0.120 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2521 | 0.120 |
Why?
| | Emergency Medical Services | 1 | 2022 | 548 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 2017 | 352 | 0.120 |
Why?
| | Sleep | 1 | 2021 | 754 | 0.120 |
Why?
| | Logistic Models | 2 | 2017 | 2064 | 0.120 |
Why?
| | Influenza, Human | 1 | 2021 | 632 | 0.110 |
Why?
| | Pneumonia | 1 | 2021 | 638 | 0.110 |
Why?
| | Disease Progression | 1 | 2022 | 2755 | 0.110 |
Why?
| | Recurrence | 1 | 2017 | 1060 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2021 | 651 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2024 | 15628 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1263 | 0.100 |
Why?
| | Cholesterol, HDL | 1 | 2014 | 205 | 0.100 |
Why?
| | Quantitative Trait, Heritable | 1 | 2014 | 126 | 0.100 |
Why?
| | Middle Aged | 9 | 2025 | 33355 | 0.100 |
Why?
| | Cannabis | 1 | 2019 | 490 | 0.100 |
Why?
| | Oximetry | 2 | 2023 | 96 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1800 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2857 | 0.090 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2011 | 116 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 2193 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2837 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7593 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2025 | 10821 | 0.080 |
Why?
| | Lung | 2 | 2024 | 4066 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2025 | 902 | 0.070 |
Why?
| | Colorado | 3 | 2025 | 4521 | 0.070 |
Why?
| | Lymph Nodes | 1 | 2011 | 493 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 2290 | 0.070 |
Why?
| | Rats | 1 | 2017 | 5676 | 0.070 |
Why?
| | Proteins | 1 | 2014 | 1012 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2025 | 3546 | 0.070 |
Why?
| | Sex Characteristics | 2 | 2023 | 766 | 0.070 |
Why?
| | Time Factors | 1 | 2017 | 6817 | 0.070 |
Why?
| | Hypoxia | 2 | 2025 | 1108 | 0.060 |
Why?
| | Databases, Factual | 2 | 2023 | 1351 | 0.060 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2017 | 26 | 0.060 |
Why?
| | Child, Preschool | 4 | 2021 | 11097 | 0.060 |
Why?
| | Burn Units | 1 | 2025 | 48 | 0.060 |
Why?
| | Phthalazines | 1 | 2025 | 45 | 0.060 |
Why?
| | Aged | 5 | 2025 | 23798 | 0.060 |
Why?
| | Bias | 2 | 2017 | 221 | 0.060 |
Why?
| | United States | 4 | 2022 | 14696 | 0.060 |
Why?
| | Melanoma | 1 | 2011 | 758 | 0.060 |
Why?
| | Community-Based Participatory Research | 1 | 2025 | 161 | 0.050 |
Why?
| | Carboplatin | 1 | 2024 | 144 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2024 | 178 | 0.050 |
Why?
| | Immunization Programs | 1 | 2025 | 219 | 0.050 |
Why?
| | Infant | 3 | 2022 | 9467 | 0.050 |
Why?
| | Paclitaxel | 1 | 2024 | 231 | 0.050 |
Why?
| | Piperazines | 1 | 2025 | 351 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 561 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 659 | 0.050 |
Why?
| | Hospitalization | 2 | 2023 | 2197 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 422 | 0.050 |
Why?
| | Tryptases | 1 | 2022 | 12 | 0.050 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.050 |
Why?
| | Substance P | 1 | 2022 | 43 | 0.050 |
Why?
| | Information Systems | 1 | 2022 | 61 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5427 | 0.050 |
Why?
| | Osteocalcin | 1 | 2021 | 36 | 0.050 |
Why?
| | Workflow | 1 | 2022 | 165 | 0.040 |
Why?
| | Ovulation | 1 | 2021 | 40 | 0.040 |
Why?
| | Estrous Cycle | 1 | 2021 | 20 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2021 | 123 | 0.040 |
Why?
| | Collagen Type I | 1 | 2021 | 133 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 308 | 0.040 |
Why?
| | Quality of Life | 2 | 2023 | 2870 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 132 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 426 | 0.040 |
Why?
| | Endoscopy | 1 | 2023 | 316 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5772 | 0.040 |
Why?
| | Guatemala | 1 | 2020 | 333 | 0.040 |
Why?
| | Ovary | 1 | 2021 | 218 | 0.040 |
Why?
| | Sleep Deprivation | 1 | 2021 | 174 | 0.040 |
Why?
| | Animals | 2 | 2021 | 37011 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2022 | 950 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 219 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 678 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1950 | 0.040 |
Why?
| | Cannabidiol | 1 | 2019 | 119 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1060 | 0.030 |
Why?
| | Body Mass Index | 2 | 2017 | 2369 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2024 | 1428 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 814 | 0.030 |
Why?
| | Dronabinol | 1 | 2019 | 230 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 643 | 0.030 |
Why?
| | Medicare | 1 | 2022 | 747 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 502 | 0.030 |
Why?
| | Communication | 1 | 2022 | 874 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1703 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1465 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2017 | 407 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1702 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1002 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1580 | 0.030 |
Why?
| | Prevalence | 1 | 2020 | 2719 | 0.030 |
Why?
| | Gene Frequency | 1 | 2014 | 521 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1161 | 0.020 |
Why?
| | Support Vector Machine | 1 | 2011 | 39 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3439 | 0.020 |
Why?
| | Exercise | 1 | 2022 | 2024 | 0.020 |
Why?
| | Young Adult | 2 | 2021 | 13243 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2021 | 6059 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4172 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3301 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1377 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10356 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2039 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3205 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2420 | 0.010 |
Why?
| | Mice | 1 | 2021 | 17843 | 0.010 |
Why?
| | Cohort Studies | 1 | 2014 | 5730 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 4031 | 0.010 |
Why?
|
|
Rice's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|